liposomal doxorubicin การใช้

• Single-drug regimens ( doxorubicin or topotecan ) do not have high response rates, but single-drug regimens of topotecan, pegylated liposomal doxorubicin, or gemcitabine are used in some cases.
• Paclitaxel used alone is another possible regimen, or it may be combined with liposomal doxorubicin, gemcitabine, cisplatin, topotecan, etoposide, or cyclophosphamide . ( See also Palliative care below .)
• A non-pegylated liposomal doxorubicin, called Myocet, is approved in Europe and Canada for treatment of metastatic breast cancer in combination with cyclophosphamide, but has not been approved by the FDA for use in the United States.
• EC145 also represents the first FA-drug conjugate to be evaluated in clinical trials, and it is currently ( 2009 ) being tested in a multi-national randomized Phase 2b trial in combination with pegylated liposomal doxorubicin ( Doxil ).
• Regimens include carboplatin combined with pegylated liposomal doxorubicin, gemcitabine, or paclitaxel . ) For recurrent germ cell tumors, an additional 4 cycles of BEP chemotherapy is the first-line treatment for those tho have been treated with surgery or platins.
• A Marketing Authorization Application ( MAA ) filing for vintafolide and etarfolatide for the treatment of patients with folate receptor-positive platinum-resistant ovarian cancer in combination with doxorubicin, pegylated liposomal doxorubicin ( PLD ), has been accepted by the European Medicines Agency.
• The European Medicines Agency ( EMA ) is reviewing the Marketing Authorization Application ( MAA ) filings for both vintafolide and etarfolatide, for the treatment of patients with folate receptor-positive platinum-resistant ovarian cancer in combination with pegylated liposomal doxorubicin ( PLD ).